Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi(National Cancer Institute), Ira L. Kraft(National Cancer Institute), Hao‐Wei Wang(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Bonnie Yates(National Institutes of Health), Cindy Delbrook(National Institutes of Health), Julie D. Zimbelman, Roger Giller(University of Colorado Denver), Maryalice Stetler‐Stevenson(National Cancer Institute), Elaine S. Jaffe(National Cancer Institute), Daniel W. Lee(University of Virginia), Jack F. Shern(National Institutes of Health), Terry J. Fry(National Cancer Institute), Nirali N. Shah(Center for Cancer Research)
Cited by 170Open Access
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the predominant subtype of Non-Hodgkin lymphoma (NHL) in adolescents and adults. Originating from a B-cell lineage, the neoplastic cells typically express pan-B- cell antigens including CD19, CD20 and CD22.[1][1] DLBCL can be highly curable, particularly with
Related Papers
No related papers found
Powered by citation graph analysis